Voyager Therapeutics Inc
NASDAQ:VYGR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.27
10.84
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Voyager Therapeutics Inc
Other Non-Cash Items
Voyager Therapeutics Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
Other Non-Cash Items
$9.2m
|
CAGR 3-Years
39%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Other Non-Cash Items
$7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
19%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Amgen Inc
NASDAQ:AMGN
|
Other Non-Cash Items
-$419m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Non-Cash Items
$742.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Non-Cash Items
$480.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
Voyager Therapeutics Inc
Glance View
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.
See Also
What is Voyager Therapeutics Inc's Other Non-Cash Items?
Other Non-Cash Items
9.2m
USD
Based on the financial report for Sep 30, 2024, Voyager Therapeutics Inc's Other Non-Cash Items amounts to 9.2m USD.
What is Voyager Therapeutics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
-3%
Over the last year, the Other Non-Cash Items growth was 1%. The average annual Other Non-Cash Items growth rates for Voyager Therapeutics Inc have been 39% over the past three years , -3% over the past five years .